Physician profile
Robert A Kaufman
NPI 1548571953
$1,303.02
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $90.81 · 2021: $322 · 2022: $342 · 2023: $386 · 2024: $27.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $321.44 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $181.28 | 2021-2023 | Imfinzi, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $151.18 | 2020-2023 | Lynparza, Keytruda |
| Janssen Biotech, INC. | $116.60 | 2020-2023 | Imbruvica, Darzalex |
| Amgen INC. | $74.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $69.70 | 2022-2023 | |
| Eisai INC. | $57.46 | 2020-2022 | |
| Genzyme Corporation | $43.01 | 2021-2022 | |
| Beigene USA, INC. | $41.32 | 2021-2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $36.98 | 2019-2022 | |
| Lilly USA, LLC | $35.54 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Abbvie INC. | $27.38 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $24.58 | 2019 | |
| Daiichi Sankyo INC. | $22.49 | 2022 | |
| G1 Therapeutics, INC. | $17.94 | 2023 | Cosela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $15.65 | 2022 | |
| Mirati Therapeutics, INC. | $14.11 | 2023 | Krazati |
| Emd Serono, INC. | $13.64 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $13.62 | 2021 | |
| Seagen INC. | $12.35 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.